SIRT2 reverses the GCN5-induced acetylation of LIFR at K620, disrupting its homodimerization, PDPK1 activation, and AKT signaling, thereby attenuating tumor growth and positioning LIFR-K620 acetylation as a biomarker and therapeutic target in PCa. This evidence concerns the gene SIRT2 and neoplasm.